1:48 PM
Mar 09, 2018
 |  BC Extra  |  Company News

CRISPR one step closer to EU trial this year

CRISPR Therapeutics AG (NASDAQ:CRSP) added $3.02 to $56.72 on Friday after it said in its earnings that the first clinical trial application (CTA) for its ex vivo gene therapy CTX001 has been accepted in Europe. The company said the CTA acceptance positions the study to be the first company-sponsored...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >